Logo

T2 Biosystems Regains Nasdaq Listing Requirements

Aug 30, 2022 | staff reporter

NEW YORK — T2 Biosystems announced Tuesday it has regained compliance with the Nasdaq's minimum market value of listed securities continued listing requirement.

On July 22, the Nasdaq notified T2 that it was out of compliance because its listed securities had been worth less than $35 million for 30 consecutive days. The company was given until Jan. 18, 2023, to regain compliance by maintaining that minimum value for at least 10 consecutive business days.

The Lexington, Massachusetts-based company regained compliance Aug. 10 to Aug. 23.

T2's stock was up less than 1 percent in early morning trading, at $.12 per share.

Filed under

Molecular Diagnostics
Business News
Infectious Disease
PCR
North America
Nasdaq
stock listing
T2 Biosystems
Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.